1. Elming MB, Nielsen JC, Haarbo J, et al. Age and outcomes of primary prevention implantable cardioverter-defibrillators in patients with nonischemic systolic heart failure. Circulation 2017;136:1772–1780.
2. Fishbein DP, Hellkamp AS, Mark DB, et al. Use of the 6-min walk distance to identify variations in treatment benefits from implantable cardioverter-defibrillator and amiodarone: results from the SCD-HeFT
(Sudden Cardiac Death in Heart Failure Trial). J Am Coll Cardiol 2014;63:2560–2568.
3. Hess PL, Al-Khatib SM, Han JY, et al. Survival benefit of the primary prevention implantable cardioverter-defibrillator among older patients: does age matter? An analysis of pooled data from 5 clinical trials. Circ Cardiovasc Qual Outcomes 2015;8:179–186.
4. Barsheshet A, Moss AJ, Huang DT, et al. Applicability of a risk score for prediction of the long-term (8-year) benefit of the implantable cardioverterdefibrillator. J Am Coll Cardiol 2012;59:2075–2079.
5. Naksuk N, Akkaya M, Adabag S. Application of the Multicenter Automatic Defibrillator Implantation Trial II risk score in a nontrial setting. Am J Cardiol 2013;112:530–532.
6. Efficacy and Safety of Implantable Cardioverter-Defibrillator (ICD) Implantation in the Elderly (I-70). https://clinicaltrials.gov/ct2/show/NCT02121158
. Updated January 21, 2020. Accessed January 22, 2020.
7. Adabag S,Wininger M, Singh SN. Letter by Adabag et al regarding article, “Age and Outcomes of Primary Prevention Implantable Cardioverter-Defibrillators in Patients With Nonischemic Systolic Heart Failure.” Circulation 2018;137:2188–2189.
8. Bibas L, Levi M, Touchette J, et al. Implications of frailty in elderly patients with electrophysiological conditions. JACC Clin Electrophysiol 2016;2:288–294.
9. Dominguez-Rodriguez A, Abreu-Gonzalez P, Jimenez-Sosa A, et al. The impact of frailty in older patients with non-ischaemic cardiomyopathy after implantation of cardiac resynchronization therapy defibrillator. Europace 2015;17:598–602.
10. Green AR, Leff B, Wang Y, et al. Geriatric conditions in patients undergoing defibrillator implantation for prevention of sudden cardiac death: prevalence and impact on mortality. Circ Cardiovasc Qual Outcomes 2016;9:23–30.
11. Bell SP, Orr NM, Dodson JA, et al. What to expect from the evolving field of geriatric cardiology. J Am Coll Cardiol 2015;66:1286–1299.
12. Cawthon PM, Marshall LM, Michael Y, et al. Frailty in older men: prevalence, progression, and relationship with mortality. J Am Geriatr Soc 2007;55:1216–1223.
13. Ensrud KE, Ewing SK, Taylor BC, et al. Comparison of 2 frailty indexes for prediction of falls, disability, fractures, and death in older women. Arch Intern Med 2008;168:382–389.
14. Ensrud KE, Ewing SK, Cawthon PM, et al. A comparison of frailty indexes for the prediction of falls, disability, fractures, and mortality in older men. J Am Geriatr Soc 2009;57:492–498.
15. Klein BE, Klein R, Knudtson MD, et al. Frailty, morbidity and survival. Arch Gerontol Geriatr 2005;41:141–149.
16. McNallan SM, Chamberlain AM, Gerber Y, et al. Measuring frailty in heart failure: a community perspective. Am Heart J 2013;166:768–774.
17. Newman AB, Gottdiener JS, Mcburnie MA, et al. Associations of subclinical cardiovascular disease with frailty. J Gerontol A Biol Sci Med Sci 2001;56:M158–M166.
18. Werner CA. The older population: 2010. 2010 Census Briefs. www.census.gov/prod/cen2010/briefs/c2010br-09.pdf. Updated November 2011. Accessed January 22, 2020.
19. Ekerstad N, Swahn E, Janzon M, et al. Frailty is independently associated with short-term outcomes for elderly patients with non-ST-segment elevation myocardial infarction. Circulation 2011;124:2397–2404.
20. Murali-Krishnan R, Iqbal J, Rowe R, et al. Impact of frailty on outcomes after percutaneous coronary intervention: a prospective cohort study. Open Heart 2015;2:e000294.
21. Shimura T, Yamamoto M, Kano S, et al. Impact of the Clinical Frailty Scale on outcomes after transcatheter aortic valve replacement. Circulation 2017;135:2013–2024.
22. Woods NF, LaCroix AZ, Gray SL, et al. Frailty: emergence and consequences in women aged 65 and older in the Women’s Health Initiative Observational Study. J Am Geriatr Soc 2005;53:1321–1330.
23. Adabag S, Vo TN, Langsetmo L, et al. Frailty as a risk factor for cardiovascular versus noncardiovascular mortality in older men: results from the MrOS Sleep (Outcomes of Sleep Disorders in Older Men) Study.
J Am Heart Assoc 2018;7:e008974.
24. Coumbe AG, Naksuk N, Newell MC, et al. Long-term follow-up of older patients with Mobitz type I second degree atrioventricular block. Heart 2013;99:334–338.
25. Voight J, Akkaya M, Somasundaram P, et al. Risk of new-onset atrial fibrillation and stroke after radiofrequency ablation of isolated, typical atrial flutter. Heart Rhythm 2014;11:1884–1889.
26. Kiely DK, Cupples LA, Lipsitz LA. Validation and comparison of two frailty indexes: the MOBILIZE Boston Study. J Am Geriatr Soc 2009;57:1532–1539.
27. Garcia S, Ko B, Adabag S. Contrast-induced nephropathy and risk of acute kidney injury and mortality after cardiac operations. Ann Thorac Surg 2012;94:772–776.
28. Naksuk N, Saab A, Li JM, et al. Incidence of appropriate shock in implantable cardioverter-defibrillator patients with improved ejection fraction. J Card Fail 2013;19:426–430.
29. Adabag S, Rector TS, Anand IS, et al. A prediction model for sudden cardiac death in patients with heart failure and preserved ejection fraction. Eur J Heart Fail 2014;16:1175–1182.
30. Adabag S, Patton KK, Buxton AE, et al. Association of implantable cardioverter defibrillators with survival in patients with and without improved ejection fraction: secondary analysis of the Sudden Cardiac Death in Heart Failure Trial. JAMA Cardiol 2017;2:767–774.
31. Anantha Narayanan M, Vakil K, Reddy YN, et al. Efficacy of implantable cardioverter-defibrillator therapy in patients with nonischemic cardiomyopathy: a systematic review and meta-analysis of randomized controlled trials. JACC Clin Electrophysiol 2017;3:962–970.
32. Deo R, Norby FL, Katz R, et al. Development and validation of a sudden cardiac death prediction model for the general population. Circulation 2016;134:806–816.
33. Adabag S, Langsetmo L. Sudden cardiac death risk prediction in heart failure with preserved ejection fraction. Heart Rhythm 2020;17:358–364.
34. Vakil K, Kazmirczak F, Sathnur N, et al. Implantable cardioverter-defibrillator use in patients with left ventricular assist devices: a systematic review and meta-analysis. JACC Heart Fail 2016;4:772–779.
35. Vakil K, Duval S, Cogswell R, et al. Impact of implantable cardioverter-defibrillators on waitlist mortality among patients awaiting heart transplantation: an UNOS/OPTN analysis. JACC Clin Electrophysiol
36. Afilalo J, Alexander KP, Mack MJ, et al. Frailty assessment in the cardiovascular care of older adults. J Am Coll Cardiol 2014;63:747–762.
37. Sanders GD, Hlatky MA, Owens DK. Cost-effectiveness of implantable cardioverter-defibrillators. N Engl J Med 2005;353:1471–1480.
38. Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001;56:M146–M156.
39. Guralnik JM, Simonsick EM, Ferrucci L, et al. A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. J Gerontol 1994;49:M85–M94.
40. Guralnik JM, Ferrucci L, Simonsick EM, et al. Lower-extremity function in persons over the age of 70 years as a predictor of subsequent disability. N Engl J Med 1995;332:556–561.
41. Jain R, Duval S, Adabag S. How accurate is the eyeball test? A comparison of physician’s subjective assessment versus statistical methods in estimating mortality risk after cardiac surgery. Circ Cardiovasc Qual Outcomes 2014;7:151–156.